Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

New class of compounds promises to revive failing hearts

23.08.2004


Nitroxyl-releasing drugs seem to strengthen cardiac contractions, relaxation in conscious dogs

Half a million Americans are diagnosed each year with heart failure, a progressively debilitating condition characterized by the heart’s declining ability to pump blood efficiently. The condition causes about 50,000 deaths annually and accounts for 1 million hospitalizations – more than for all forms of cancer combined.
Since the 1980s, nitroglycerin and other medications that release nitric oxide (NO) into the bloodstream have been the usual approach to treating this condition. Though these drugs benefit the ailing heart by improving its ability to relax, they also have a negative flipside: they leave the heart with a diminished capacity for pumping.


Hoping to improve on that formula, researchers at The Johns Hopkins University have developed a new class of NO-based compounds called nitroxyl (HNO) precursors that produce HNO. In early studies, these compounds seem to play a role in protecting the cardiovascular system from further damage during heart failure and in restoring function to organs affected by the debilitating condition. Scientists will announce their results in late August at the American Chemical Society’s annual summer meeting, held this year in Philadelphia.

"Our results are preliminary, but very promising," said John P. Toscano, professor in the Chemistry Department in the Krieger School of Arts and Sciences at Johns Hopkins. "Our goal is not only to develop new classes of nitroxyl precursors, but also to figure out the mechanisms by which they seem to affect heart function. This has the potential to lead to alternative treatments for cardiac failure in humans. But we are still in the very early testing stage."

Toscano’s research partner, Nazareno Paolocci, assistant professor in the Department of Cardiology at The Johns Hopkins School of Medicine, administered normal, conscious dogs and those with heart failure with a compound called Angeli’s salt, which generates HNO. It turned out that this treatment doubled the dogs’ hearts’ ability to pump and enhanced their ability to relax between contractions -- a promising development.

"Our previous work in collaboration with Dr. David A Kass (of Johns Hopkins) and Dr. David A Wink (of the National Cancer Institute) has shown that nitroxyl donors appear to be very good candidates to treat failing hearts that are characterized by pressure overload, poor contractile function and delayed relaxation. Moreover, these compounds can be successfully combined with other drugs used in heart failure patients, namely, beta-blockers," Paolocci said.

Essentially all physiological studies probing the effects of nitroxyl have used Angeli’s salt as a donor of that substance, prompting Toscano’s team to set to work to develop new sources. New nitroxyl donors not only would confirm that the physiological effects seen with Angeli’s salt are truly due to HNO, but they also would help researchers determine if the rate of HNO release had any effect on the resulting physiological response.

"One of the main reactions of nitroxyl is dimerization – that is, the reaction of one HNO molecule with another – which is dependent on the local concentration," Toscano said. "So, compounds that release HNO at faster rates generate higher initial concentrations of it and therefore may result in HNO being consumed by the dimerization reaction, rather than being available to elicit the desired physiologic response."

So far, Toscano’s team has cultivated one class of compounds based on the reaction of certain secondary amines with nitric oxide to form compounds called diazeniumdiolates, which traditionally are NO donors, but have been turned into HNO donors by Toscano’s team.

Paolocci and his team have tested two of these derivatives – one a pure HNO donor, which behaves similarly to Angeli’s salt and one a pure NO donor, which behaves analogously to standard NO donors – on dogs to assess their cardiovascular action.

"We’re very optimistic with what we have seen so far," Toscano said. "This looks promising. We know that NO is an important biological molecule, and we are just beginning to learn that HNO may, in potentially very different ways, be just as important."

Lisa DeNike | EurekAlert!
Further information:
http://www.jhu.edu

More articles from Health and Medicine:

nachricht Tracking movement of immune cells identifies key first steps in inflammatory arthritis
23.01.2017 | Massachusetts General Hospital

nachricht Team discovers how bacteria exploit a chink in the body's armor
20.01.2017 | University of Illinois at Urbana-Champaign

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Quantum optical sensor for the first time tested in space – with a laser system from Berlin

For the first time ever, a cloud of ultra-cold atoms has been successfully created in space on board of a sounding rocket. The MAIUS mission demonstrates that quantum optical sensors can be operated even in harsh environments like space – a prerequi-site for finding answers to the most challenging questions of fundamental physics and an important innovation driver for everyday applications.

According to Albert Einstein's Equivalence Principle, all bodies are accelerated at the same rate by the Earth's gravity, regardless of their properties. This...

Im Focus: Traffic jam in empty space

New success for Konstanz physicists in studying the quantum vacuum

An important step towards a completely new experimental access to quantum physics has been made at University of Konstanz. The team of scientists headed by...

Im Focus: How gut bacteria can make us ill

HZI researchers decipher infection mechanisms of Yersinia and immune responses of the host

Yersiniae cause severe intestinal infections. Studies using Yersinia pseudotuberculosis as a model organism aim to elucidate the infection mechanisms of these...

Im Focus: Interfacial Superconductivity: Magnetic and superconducting order revealed simultaneously

Researchers from the University of Hamburg in Germany, in collaboration with colleagues from the University of Aarhus in Denmark, have synthesized a new superconducting material by growing a few layers of an antiferromagnetic transition-metal chalcogenide on a bismuth-based topological insulator, both being non-superconducting materials.

While superconductivity and magnetism are generally believed to be mutually exclusive, surprisingly, in this new material, superconducting correlations...

Im Focus: Studying fundamental particles in materials

Laser-driving of semimetals allows creating novel quasiparticle states within condensed matter systems and switching between different states on ultrafast time scales

Studying properties of fundamental particles in condensed matter systems is a promising approach to quantum field theory. Quasiparticles offer the opportunity...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

Sustainable Water use in Agriculture in Eastern Europe and Central Asia

19.01.2017 | Event News

12V, 48V, high-voltage – trends in E/E automotive architecture

10.01.2017 | Event News

2nd Conference on Non-Textual Information on 10 and 11 May 2017 in Hannover

09.01.2017 | Event News

 
Latest News

Tracking movement of immune cells identifies key first steps in inflammatory arthritis

23.01.2017 | Health and Medicine

Electrocatalysis can advance green transition

23.01.2017 | Physics and Astronomy

New technology for mass-production of complex molded composite components

23.01.2017 | Process Engineering

VideoLinks
B2B-VideoLinks
More VideoLinks >>>